Application of benvitimod on psoriasis: A systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis - 22/10/21

Doi : 10.1016/j.therap.2021.09.005

Lianghong Chen ^a,^b, Yan Wu ^a, Bihuan Xiao ^a, Xinghua Gao ^a, Yan Sun ^a,⁎
^a Department of Dermatology, The First Hospital of China Medical University, 110001 Shenyang, China
^b Department of Emergency Medicine, Shengjing Hospital of China Medical University, 110004 Shenyang, China

^⁎Corresponding author.

En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Friday 22 October 2021
This article has been published in an issue click here to access

Summary

Background

We conducted this systematic review to clarify the efficacy and safety of benvitimod on psoriasis.

Methods

We searched the databases of PubMed, China National Knowledge infrastructure, Cochrane Library, Embase, Web of science to identify randomized controlled trials (RCTs) of benvitimod on psoriasis up to April 2021.

Results

Five RCTs of benvitimod on psoriasis were included. A total of 1237 patients were included. 0.5% or 1.0% benvitimod was applied topically once or twice a day. More patients in benvitimod group achieved PASI 90, PASI 75, PASI 50 and BSA reduction than placebo at Week 12. More patients in benvitimod group achieved PGA 0 or 1 than placebo since Week 6. There were no statistical significances in efficacies of benvitimod at different concentrations and frequencies.